Market Overview

UPDATE: Jefferies Raises PT on AbbVie on Attractive Valuation

Johnson & Johnson Downgraded On Hefty Valuation Compared To Peers
Watch These 8 Huge Call Purchases In Tuesday Trade

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $45.00 to $50.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

AbbVie closed on Tuesday at $42.55.

Latest Ratings for ABBV

Sep 2017JefferiesMaintainsBuy
Aug 2017Evercore ISI GroupInitiates Coverage OnOutperform
Jul 2017Deutsche BankMaintainsHold

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (ABBV)

View Comments and Join the Discussion!